Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Paul Copeland MD

Paul M. Copeland MD

Chief, Endocrinology Division, North Shore Medical Center, Salem, Massachusetts; Obesity Medicine Physician, MGH Weight Center, and Clinical Affiliate, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts; Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts
Dr. Paul Copeland received his M.D. degree from Yale University School of Medicine, where he also earned an M.Phil. in Pharmacology. He did his residency in Medicine at the Hospital of the University of Pennsylvania and then completed a fellowship in Endocrinology at Massachusetts General Hospital. Dr. Copeland currently serves as Chief of Endocrinology at North Shore Medical Center. He is also a Clinical Affiliate of the Endocrine Unit at Massachusetts General Hospital and Assistant Professor of Medicine, part time, at Harvard Medical School. Dr. Copeland is an author of over 50 articles, reviews, chapters, and case reports related to endocrinology. In addition to his work in general endocrinology, Dr. Copeland has worked at the MGH Weight Center since 2001 and is currently the Center’s Endocrine Consultant. He was certified by the initial exam of the American Board of Obesity Medicine. He is the recipient of the Endocrine Society’s 2014 Outstanding Clinical Practitioner Laureate Award.


Dr. Copeland was on an advisory panel for diabetes for Novo Nordisk, which was completed October 2019.